Eye on the Market Coronavirus tracking: State by State reports

Michael Cembalest
JP Morgan

Contents: virus tracking reports for all 50 states + DC

Chart 1: Infections vs hospitalizations
Chart 2: Daily deaths vs case fatality rates
Chart 3: Infections, hospitalizations and mortality
Chart 4: Deaths as a % of current hospitalizations
Chart 5: Daily number of tests and percentage of positive tests
Chart 6: Infections vs doctor visits with COVID-like symptoms
Chart 7: Hospital bed and ICU bed utilization rates vs 2018 averages
Chart 8: Infections and percentage of positive tests

States appear in this report in descending order of State GDP.

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.
California virus tracking

- New infections per mm vs active hospitalizations per mm

California virus tracking

- Current hospitalizations and daily infections vs daily deaths

California virus tracking

- Positive tests/total tests vs total daily tests (000's)

California virus tracking

- Hospital utilization rates

California virus tracking

- New daily infections per mm vs % of doctor visits with COVID-like symptoms
Eye on the Market Coronavirus tracking: New York

New York virus tracking

- New infections per mm
- Active hospitalizations per mm

Source: COVID Tracking Project, JP Morgan. 11/15/2020. 7 day avgs.

New York virus tracking

- Current hospitalizations and daily infections
- Daily deaths

Source: COVID Tracking Project, JP Morgan. 11/15/2020. 7 day avgs.

New York virus tracking

- New daily infections (LHS)
- Cur Hosp (LHS)
- Daily deaths (RHS)

Source: COVID Tracking Project, JP Morgan. 11/15/2020. 7 day avgs.

New York virus tracking

- Daily deaths as a % of current hospitalizations

Source: COVID Tracking Project, JP Morgan. 11/15/2020. 7 day avgs.

New York virus tracking

- Positive tests/total tests
- Total daily tests (000's)

Source: COVID Tracking Project, CMU, JP Morgan. 11/15/2020. 7 day avgs.

New York virus tracking

- New infections per mm
- % of doctor visits with COVID-like symptoms

Source: COVID Tracking, CMU. 11/15/2020. 7 day avgs.

New York virus tracking

- Hospital bed utilization rate
- ICU bed utilization rate


New York virus tracking

- New daily infections
- Testing rate

Source: COVID Tracking Project, CMU. 11/15/2020. 7 day avgs.
Eye on the Market Coronavirus tracking: Washington

Michael Cembalest

JP Morgan

Washington virus tracking

Current hospitalizations and daily infections

Daily deaths

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Washington virus tracking

Positive tests/total tests

Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Washington virus tracking

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
Eye on the Market Coronavirus tracking: Colorado

Michael Cembalest
JP Morgan

Colorado virus tracking

New infections per mm  Active hospitalizations per mm

Daily deaths per mm
Case fatality rate, infections lagged 18 days

Daily deaths as a % of current hospitalizations

New daily infections per mm  Percentage

Hospital utilization rates

Hospital bed utilization rate
2018 hosp bed utilization rate
ICU bed utilization rate
2018 ICU bed utilization rate

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.
Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

South Carolina virus tracking

Current hospitalizations and daily infections

Daily deaths

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

South Carolina virus tracking

Positive tests/total tests

Total daily tests (000's)

Source: COVID Tracking Project, CMU, JPMAM. 11/15/2020. 7 day avgs.

South Carolina virus tracking

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
Kentucky virus tracking

Current hospitalizations and daily infections

Daily deaths

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Kentucky virus tracking

Positive tests/total tests

Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Kentucky virus tracking

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
**Iowa virus tracking**

![Graph showing new infections per mm and active hospitalizations per mm.](image)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Iowa virus tracking**

Current hospitalizations and daily infections

![Graph showing current hospitalizations and daily deaths.](image)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Iowa virus tracking**

Positive tests/total tests

![Graph showing positive testing rate and daily # of tests.](image)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Iowa virus tracking**

Hospital utilization rates

![Graph showing hospital bed utilization rate and ICU bed utilization rate.](image)

Source: HHS, UNC, JPMAM. 11/14/2020.
Arkansas virus tracking

New infections per mm vs. Active hospitalizations per mm

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Arkansas virus tracking

Daily infections vs. Daily deaths vs. Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Arkansas virus tracking

Positive tests/total tests vs. Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Arkansas virus tracking

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.

Arkansas virus tracking

New daily infections per mm vs. Positive testing rate

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.
Eye on the Market Coronavirus tracking: Nebraska

Michael Cembalest
JP Morgan

Nebraska virus tracking

<---New infections per mm  Active hospitalizations per mm --->

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Nebraska virus tracking
Current hospitalizations and daily infections

Daily deaths

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Nebraska virus tracking
Positive tests/total tests

Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Nebraska virus tracking
Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
Eye on the Market Coronavirus tracking: Hawaii

Michael Cembalest
JP Morgan

Hawaii virus tracking

Current hospitalizations and daily infections

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Daily deaths as a % of current hospitalizations

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Positive tests/total tests

Total daily tests (000’s)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
Delaware virus tracking

New infections per mm
Active hospitalizations per mm

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Delaware virus tracking

Current hospitalizations and daily infections
Daily deaths

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Delaware virus tracking

Positive tests/total tests
Total daily tests (000's)

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

Delaware virus tracking

Hospital utilization rates

Source: HHS, UNC, JPMAM. 11/14/2020.
Montana virus tracking

New infections per mm - Active hospitalizations per mm

Montana virus tracking

Current hospitalizations and daily infections

Daily deaths

Montana virus tracking

Positive tests/total tests - Total daily tests (000's)

Montana virus tracking

Hospital utilization rates

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.
**South Dakota virus tracking**

**New infections per mm**

- **Active hospitalizations per mm**

**Source**: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Daily deaths**

- **Case fatality rate, infections lagged 18 days**

**Source**: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Daily deaths as a % of current hospitalizations**

**Source**: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Positive tests/total tests**

- **Total daily tests (000’s)**

**Source**: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.

**Hospital utilization rates**

- **Hospital bed utilization rate**
- **ICU bed utilization rate**
- **2018 hosp bed utilization rate**
- **2018 ICU bed utilization rate**

**Source**: HHS, UNC, JPMAM. 11/14/2020.
Vermont virus tracking

- New infections per mm
- Active hospitalizations per mm

Vermont virus tracking

- Daily deaths per mm
- Case fatality rate, infections lagged 18 days

Vermont virus tracking

- Daily deaths as a % of current hospitalizations

Vermont virus tracking

- Positive tests/total tests
- Total daily tests (000's)

Vermont virus tracking

- Hospital bed utilization rate
- ICU bed utilization rate
- 2018 hosp bed utilization rate
- 2018 ICU bed utilization rate

Source: COVID Tracking Project, JPMAM. 11/15/2020. 7 day avgs.
IMPORTANT INFORMATION

The views, opinions and estimates expressed herein constitute Michael Cembalest’s judgment based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such. The views contained herein are not to be taken as advice or a recommendation to buy or sell any investment in any jurisdiction, nor is it a commitment from J.P. Morgan or any of its subsidiaries to participate in any of the transactions mentioned herein. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions and current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of production. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Both past performance and yields are not reliable indicators of current and future results.

Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates.

For J.P. Morgan Asset Management Clients:
J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.
To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://am.jpmorgan.com/global/privacy.

ACCESSIBILITY
For U.S. only: If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.
This communication is issued by the following entities:
In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients’ use only, by local J.P. Morgan entities, as the case may be.; in Canada, for institutional clients’ use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à.r.l. In Asia Pacific (“APAC”), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong; JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number “Kanto Local Finance Bureau (Financial Instruments Firm) No. 330”); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919). For all other markets in APAC, to intended recipients only.

For J.P. Morgan Private Bank Clients:
ACCESSIBILITY
J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. Please direct any accessibility issues to the Private Bank Client Service Center at 1-866-265-1727.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION
In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPM”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Trèves, L-2633, Senningerberg, Luxembourg, R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is a credit institution in accordance with the Law of 5th April 1843. In the United...
With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission—CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JP Morgan Chase & Co. All rights reserved.